



VirClia® MONOTEST

The Best Diagnostic Solution for Invasive Candidiasis

INVASIVE CANDIDIASIS (CAGTA) VIRCLIA IgG MONOTEST

Indirect chemiluminescent immunoassay (CLIA) to detect IgG antibodies against antigens located on the cell wall surface of the micelium of *Candida albicans* (CAGTA *Candida albicans* germ tube antibody) in human serum/plasma.

PRODUCT FEATURES

- Discriminates between infection and colonization
- High Negative Predictive Value (NPV)
- Highly convenient solution to urgent samples
- Simple and automated protocol that provides results within 1 hour
- Sample dispensed from primary tube
- Objective method with extraordinary sensitivity and accuracy in the results
- Monotest format with ready-to-use reagents
- CAGTA (*Candida albicans* germ tube antibody) is widely recognized in the scientific literature as an excellent diagnostic tool



Ref. VCM094 - 24 tests



INVASIVE CANDIDIASIS

Invasive candidiasis is an opportunistic disease of fungal etiology that can occur when *Candida* yeasts enter the bloodstream and spreads to other parts of the body causing an infection.

Antibodies to CAGTA are normally present in sera from patients with invasive candidiasis caused by *C. albicans* and other species of this genus.

Patients at high risk for developing candidemia include:

- Intensive care unit (ICU) patients.
- Long-stay hospitalized patients.
- Patients with major surgery.
- Patients with a central venous catheter.
- People whose immune systems are weakened.
- Patients receiving broad spectrum antibiotic therapy.
- Very low-birth-weight infants.

Vircell has launched a new test for the early detection of invasive candidiasis (IC) that discriminates infection from colonization. A prompt and accurate diagnosis is essential as a delay of only 12 hours may affect survival significantly.


With this method, clinicians will be able to specifically treat the infective phase of *Candida*, avoiding for many patients to receive unnecessary, expensive and sometimes toxic antifungals.

INVASIVE CANDIDIASIS (CAGTA) VIRCLIA® IgG MONOTEST can bring significant advances to clinical laboratories where giving an informed result can truly make the difference in saving someone's life.

New test for the early detection of invasive candidiasis

Why INVASIVE CANDIDIASIS (CAGTA) VIRCLIA® IgG MONOTEST should be part of your lab routine?

- ▶ **Results in 1 hour**
Early diagnosis and treatment are associated with a better prognosis in invasive candidiasis.
- ▶ **Monotest format**
All reagents are included and ready-to-use.
- ▶ **Better patient care**
Giving unnecessary and expensive antifungal drugs to patients should be avoided.
- ▶ **Save costs**
Using the right diagnostic tool could lead to substantial reductions in total inpatient cost.



Clancy, C. J. and Nguyen, M. H. (2018) Diagnosing Invasive Candidiasis. *Journal of Clinical Microbiology*. **56** (5), e01909-17.

Clancy, C. J. and Nguyen, M. H. (2018) Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences. *Journal of Fungi*. **4**, 27.

Lo Cascio, G. et al. (2018) Value of beta-D-glucan and CAGTA biomarkers in diagnosing invasive candidiasis among medical and surgical patients. ECCMID, Madrid, Spain.

Marchi, E. et al. (2018) Performance of the association of two markers for invasive candidiasis (IC): (1-3)-beta-D-glucan and *C. albicans* germ tube antibodies (CAGTA). ECCMID, Madrid, Spain.